These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38945393)

  • 1. Nanosuspensions: Enhancing drug bioavailability through nanonization.
    Chavhan R
    Ann Pharm Fr; 2024 Jun; ():. PubMed ID: 38945393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
    Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
    Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanosuspensions: a promising drug delivery strategy.
    Patravale VB; Date AA; Kulkarni RM
    J Pharm Pharmacol; 2004 Jul; 56(7):827-40. PubMed ID: 15233860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
    Agarwal V; Bajpai M
    Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanosuspensions in ophthalmology: Overcoming challenges and enhancing drug delivery for eye diseases.
    Fathi-Karkan S; Amiri Ramsheh N; Arkaban H; Narooie-Noori F; Sargazi S; Mirinejad S; Roostaee M; Sargazi S; Barani M; Malahat Shadman S; Althomali RH; Rahman MM
    Int J Pharm; 2024 Jun; 658():124226. PubMed ID: 38744414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles in the pharmaceutical industry and the use of supercritical fluid technologies for nanoparticle production.
    Sheth P; Sandhu H; Singhal D; Malick W; Shah N; Kislalioglu MS
    Curr Drug Deliv; 2012 May; 9(3):269-84. PubMed ID: 22283656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation Strategies of Nanosuspensions for Various Administration Routes.
    Pınar SG; Oktay AN; Karaküçük AE; Çelebi N
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of nanosuspensions in drug delivery systems.
    Jacob S; Nair AB; Shah J
    Biomater Res; 2020; 24():3. PubMed ID: 31969986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
    Thakkar HP; Patel BV; Thakkar SP
    J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of recent patents on nanosuspension.
    Modh N; Mehta D; Parejiya P; Popat A; Barot B
    Recent Pat Drug Deliv Formul; 2014; 8(2):144-54. PubMed ID: 24758487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Nanosuspension Technology for Drug Delivery.
    Arora D; Khurana B; Rath G; Nanda S; Goyal AK
    Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
    Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
    Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
    Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
    Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
    Kocbek P; Baumgartner S; Kristl J
    Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
    Chavhan SS; Petkar KC; Sawant KK
    Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization.
    Kanthamneni N; Valiveti S; Patel M; Xia H; Tseng YC
    Int J Pharm Investig; 2016; 6(4):218-224. PubMed ID: 28123991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
    Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
    Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosuspension: Principles, Perspectives and Practices.
    Singh SK; Vaidya Y; Gulati M; Bhattacharya S; Garg V; Pandey NK
    Curr Drug Deliv; 2016; 13(8):1222-1246. PubMed ID: 26721266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
    Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
    Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.